Table 1.
Comparison of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67, and enhancer of zeste homolog 2 biomarkers between primary lesions and metastatic lesions in breast cancer patients (n = 96)
| Biomarker | Primary lesions | Metastatic lesions | P-value |
|---|---|---|---|
| ER status, n (%) | |||
| positive | 51 (53.1) | 41 (42.7) | 0.149 |
| negative | 45 (46.9) | 55 (57.3) | |
| PR status, n (%) | |||
| positive | 47 (49.0) | 39 (40.6) | 0.246 |
| negative | 49 (51.0) | 57 (59.4) | |
| HER2 status, n (%) | |||
| positive | 16 (16.7) | 14 (14.6) | 0.691 |
| negative | 80 (83.3) | 82 (85.4) | |
| Ki-67 expression, n (%) | |||
| high | 55 (57.3) | 72 (75.0) | 0.010* |
| low | 41 (42.7) | 24 (25.0) | |
| EZH2 expression, n (%) | |||
| high | 54 (56.3) | 79 (82.3) | <0.0001* |
| low | 42 (43.7) | 17 (17.7) | |
| Molecular subtype, n (%) | |||
| luminal Aa | 31 (32.3) | 19 (19.8) | 0.304 |
| luminal Bb | 22 (22.9) | 29 (30.2) | |
| luminal HER2c | 5 (5.2) | 5 (5.2) | |
| HER2-typed | 11 (11.5) | 9 (9.4) | |
| TNBCe | 27 (28.1) | 34 (35.4) | |
Abbreviations: ER estrogen receptor, EZH2 enhancer of zeste homolog 2, HER2 human epidermal growth factor receptor 2, PR progesterone receptor, TNBC triple-negative breast cancer
aLuminal A = ER and/or PR+, HER2−, and low Ki-67 expression
bLuminal B = ER and/or PR+, HER2−, and high Ki-67 expression
cLuminal HER2 = ER and/or PR+, HER2+
dHER2-type = ER and PR−, HER2+
eTNBC = ER and PR−, HER2−
*Indicates values that are statistically significant (P < 0.05)